Locally-acting ligand trap based on a modified follistatin-Fc fusion protein. Injected directly into target muscles to inhibit myostatin locally, promoting site-specific muscle growth without systemic effects.
Inject IM directly into target muscle every 3 weeks. Site-specific action. Monitor injection site reactions. Originally developed for FSHD.
Log doses, calculate reconstitution, set reminders, and get AI guidance for ACE-083.
Start Free Trial